- Marijuana Prevention Initiative September 9, 2021
- Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions 27 March 2020
- Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use 2019 2019, July 8
Marijuana Prevention Initiative
The San Diego County Marijuana Prevention Initiative (MPI) September 9, 2021
The San Diego County Marijuana Prevention Initiative (MPI) launched its Marijuana Drug Interactions Project along with 17 partner pharmacies. Marijuana use is increasing and so are emergency room visits related to drug interactions between patients prescribed medicine and THC/CBD…
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
National Center for Biotechonology Information 2019 July 8
Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential for pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs). Prescribing information for federally approved products containing CBD were reviewed. Nearly one-half of CBD users experienced ADEs, which displayed a general dose-response relationship. Common ADEs include transaminase elevations, sedation, sleep disturbances, infection, and anemia. Given CBD effects on common biological targets implicated in drug metabolism (e.g., CYP3A4/2C19) and excretion (e.g., P-glycoprotein), the potential for DDIs with commonly used medication is high. These effects should be considered in the risk-benefit assessment of CBD therapy and patients and consumers made aware of potential safety issues with CBD use…
Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
Center for Drug Evaluation & Safety, 27 March 2020
Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis. While the safety of THC and cannabis has been extrapolated from millennia of recreational use, medical marijuana programs have increased exposure among medically complex individuals with comorbid conditions and many co-prescribed medications. Thus, THC should be recognized as a pharmacologically complex compound with potential for drug-drug interactions and adverse drug events. This review summarizes potential adverse drug events related to THC when combined with other medications. Pharmacodynamic interactions include neurological effects, impact on the cardiovascular system, and risk of infection. Many interactions may be unavoidable, dose-limiting, or a barrier to THC-based therapy…
